Immunotherapy drug may delay return of aggressive head and neck cancers

NCT ID NCT02841748

Completed Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving the immunotherapy drug pembrolizumab for one year after standard treatment could help prevent head and neck cancer from coming back in 100 patients at high risk for recurrence. Participants received either pembrolizumab or a placebo. The main goal was to see if the drug improved the time patients lived without their cancer progressing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Contacts and locations

Locations

Emory University Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Rush University Medical Center

Chicago, Illinois, 60612, United States
University of Chicago Medical Center

Chicago, Illinois, 60637, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.